摘要:
Polymorphic forms of N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]-phenyl]-2E-2-propenamide free base and salts thereof are prepared by various processes.
摘要:
The present invention provides an efficient, safe and cost effective way to prepare 5-(4-methyl-1 H -imidazol-1-yl)-3-(trifluoromethyl)-benzenamine which is a key intermediate for the preparation of substituted pyrimidinylaminobenzamides of formula (II):
摘要:
N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamide and starting materials therefor are prepared by new synthetic methods.
摘要:
The present invention provides an efficient, safe and cost effective way to prepare 5-(4-methyl-1 H -imidazol-1-yl)-3-(trifluoromethyl)-benzenamine which is a key intermediate for the preparation of substituted pyrimidinylaminobenzamides of formula (II):
摘要:
The present invention provides an efficient, safe and cost effective way to prepare 5-(4-methyl-1 H -imidazol-1-yl)-3-(trifluoromethyl)-benzenamine which is a key intermediate for the preparation of substituted pyrimidinylaminobenzamides of formula (II):
摘要:
The present invention provides an efficient, safe and cost effective way to prepare 5-(4-methyl-1 H -imidazol-1-yl)-3-(trifluoromethyl)-benzenamine which is a key intermediate for the preparation of substituted pyrimidinylaminobenzamides of formula (II):
摘要:
A process for the production of a compound of formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable prodrug ester thereof, comprising cleaving a lactam of formula (II) wherein the symbols are as defined, with a base; and precursors therefor and processes for the preparation of the precursors. The compounds of formula (I) are pharmaceutically active compounds which are selective inhibitors of Cyclooxygenase (II).
摘要:
This invention provides pharmaceutical compositions comprising polymeric matrices, especially those comprising IL-6 as an active ingredient. Specific novel poly(ethylene carbomate) polymers are also provided for more general use as matrix materials in sustained release compositions containing pharmacologically active compounds, as are methods of using of IL-6 for treatment of conditions mediated by IL-1 and/or TNF á, e.g., certain autoimmune and inflammatory conditions, as well as septic shock.